Samuel M. Shor, M.D.

June 29, 2017

Dr. Samuel M. Shor, M.D. recently made a presentation to the National Capital Lyme Disease Association providing an update on the clinical research he is conducting with Ceres Nanosciences, a Northern Virginian based biotechnology company.  Included in his presentation was a description of his upcoming research study focused on a new release of the urine based Nanotrap Lyme antigen test for use when a patient presents with a tick attachment, tick bite, or an erythema migrans (EM) rash.  This presentation confirms the idea that Nanotrap technology developed by Ceres Nanosciences and George Mason University could possibly revolutionize diagnostics for Lyme disease.

Dr. Samuel M. Shor, M.D. recently made a presentation to the National Capital Lyme Disease Association providing an update on the clinical research he is conducting with Ceres Nanosciences, a Northern Virginian based biotechnology company.

- Samuel M. Shor, M.D. at Internal Medicine of Northern Virginia